Trevogrumab Dosing Calculator

Dose

Dose details from ongoing trial

Frequency

Every 4 weeks

Duration

26 weeks (interim) to 52 weeks (full trial)

Route

Subcutaneous injection

Phase 2 combination trial with semaglutide; not yet commercially available

Dose

Trevogrumab 400 mg SC + garetosmab 10 mg/kg IV in combination with semaglutide 2.4 mg SC weekly. At 26 weeks, the triplet preserved 80.9% of lean mass and increased fat loss 27.3% vs semaglutide alone, but had a 28.3% discontinuation rate.

Frequency

Subcutaneous (trevogrumab) + IV (garetosmab) + SC weekly (semaglutide)

Duration

26-week weight-loss phase

The triplet therapy showed superior lean mass preservation and fat loss but had significantly higher discontinuation rates (28.3% vs 4-10% in other groups) and two deaths. This arm may not advance in its current form.

Dose

Single and multiple doses of trevogrumab SC alone or in combination with escalating doses of garetosmab IV. Dose-dependent increases in MRI-quantitated thigh muscle volume observed with combination therapy.

Frequency

Single dose and multiple-dose regimens tested

Duration

Variable duration across two study parts

Phase 1 trial (NCT02943239) in 82 subjects. Specific doses tested not fully disclosed in public reports. Combination blockade showed greater muscle gains than either antibody alone.

Dose

After the 26-week weight-loss phase, participants are randomized to higher-dose trevogrumab monotherapy or placebo through week 52. This phase evaluates whether trevogrumab alone can maintain body composition improvements without concurrent semaglutide.

Frequency

Higher-dose trevogrumab SC monotherapy

Duration

26 weeks (weeks 27-52)

Results from the weight-maintenance phase have not been reported. This phase will provide important data on trevogrumab's standalone effects on lean mass and body composition.

How much bacteriostatic water should I add to a 15 mg vial of Trevogrumab?

The community standard is 2 mL of bacteriostatic water for a 15 mg Trevogrumab vial. That gives a concentration of 7.50 mg/mL, so a 200 mg dose is 2666.7 units on a U-100 insulin syringe. Adding 1 mL instead doubles the concentration to 15.00 mg/mL and halves the draw to 1333.3 units. Less water = smaller injection volume but harder to measure precisely.

How many syringe units is a 200 mg dose of Trevogrumab?

On a standard U-100 insulin syringe, a 200 mg dose of Trevogrumab is 2666.7 units when the 15 mg vial is reconstituted with 2 mL of bacteriostatic water (7.50 mg/mL). If you use 1 mL of bac water instead, draw 1333.3 units (15.00 mg/mL).

What is the standard Trevogrumab dose?

Clinical protocols for Trevogrumab typically use 200 mg–400 mg once daily via subcutaneous injection. 200 mg is a common starting dose. Both 200 mg and 400 mg doses showed similar lean mass preservation (50.8% vs 51.3%). The higher dose showed modestly greater weight loss and fat loss. Specific dosing interval (Q2W or Q4W) should be confirmed from full trial publication.

Where do you inject Trevogrumab?

Trevogrumab is typically administered subcutaneously. Common subcutaneous sites are the lower abdomen (at least an inch from the navel), the outer thigh, and the love handles. Rotate sites with each injection to reduce localized irritation and bruising.

Can I use sterile water instead of bacteriostatic water for Trevogrumab?

Bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) is strongly preferred for multi-dose vials like Trevogrumab because it inhibits microbial growth and lets a single vial be used over multiple weeks. Sterile water has no preservative and should generally be reserved for single-use preparations only.